Movement Disorders

The senior vice president of clinical development for Lundbeck discusses the mechanism and early clinical promise of Lu AF28996, an oral dual D1/D2 agonist for advanced Parkinson disease. [WATCH TIME: 3 minutes]

A data-driven slideshow for National Public Health Week highlights the global burden of neurologic diseases, featuring key statistics on prevalence, disability, and workforce gaps across major conditions.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 10, 2026.

Steven Markos, MD, a physician at Hackensack Meridian JFK Johnson Rehabilitation Institute, discussed a two-week inpatient rehabilitation program and its impact on functional and speech outcomes in Parkinson disease.

The professor of neurology at Mayo Clinic spoke about the current state of biomarker research in MSA. [WATCH TIME: 8 minutes]

In a preclinical study, subthalamic nucleus (STN) low-beta power negatively correlated with wake quantity, whereas STN and motor cortex high-beta power demonstrated a positive correlation with wakefulness.

Jonathan Charlesworth, PhD, chief scientific officer at Noctrix Health, discusses emerging research connecting restless legs syndrome with neurologic conditions such as multiple sclerosis, and the role of the FDA-cleared Nidra wearable device in patient care.

New data from the pivotal study of investigational therapy zilganersen in Alexander disease will be presented at the 2026 American Academy of Neurology (AAN) annual meeting in Chicago.

A new retrospective analysis presented at AD/PD 2026 showed that cutaneous phosphorylated α-synuclein testing reduced diagnostic and management-related health care expenditures.

Levacetylleucine met its primary end point in a phase 3 trial of patients living with ataxia-telangiectasia, with no drug-related serious adverse events reported, supporting the sNDA.

An analysis of baseline data from the phase 2b LUMA study suggested that keystroke dynamics captured through a smartphone-based typing task could provide a reliable method for assessing disease progression in Parkinson disease.

Early ASPIRO trial data show autologous stem-cell dopamine precursors stay safe at 12 months, with improved PD motor scores and PET-confirmed grafting.

UK platform trial enrolls 1,600 with Parkinson’s to rapidly test telmisartan, terazosin and new candidates via shared placebo and virtual visits.

A global survey of neurologists and psychiatrists found that although tetrabenazine remains widely used for tardive dyskinesia and Huntington disease–related chorea, side effects frequently prevent optimal dose titration and lead to treatment discontinuation.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with AAN President Natalia Rost, MD, MPH. [LISTEN TIME: 16 minutes]

Praxis files FDA NDAs for ulixacaltamide and relutrigine, highlighting phase 3 tremor gains and major seizure cuts in rare DEEs.

Xenos Mason, MD, a neurologist specializing in movement disorders, provides commentary on an early-stage study evaluating induced pluripotent stem cells for patients with Parkinson disease.

Bruce Ovbiagele, MD, MSc, MAS, MBA, founding president of the Society for Equity Neuroscience (SEQUINS) reflects on Black History Month, SEQUINS initiatives, and the policy and guideline reforms needed to advance brain health equity in 2026 and beyond.

A movement disorder specialist at Northwestern Medicine discussed developments in disease-modifying research, adaptive clinical trial designs, and evolving device-based therapies in Parkinson disease. [WATCH TIME: 5 minutes]

Neurology experts highlighted ongoing developments in artificial intelligence applications, disease-modifying mechanisms, and genetic therapies expected to undergo evaluation. [WATCH TIME: 9 minutes]

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

As part of National Women Physicians Day, a group of women clinicians discussed various topics in the care for women with movement disorders.

Claire Henchcliffe, MD, DPhil, an international leader in Parkinson disease research, reflects on mentorship, leadership development, and the systemic changes needed to support long-term success for women in neurology and clinical neuroscience.

Janis Miyasaki, MD, MEd, FRCPC, FAAN, a pioneer in neuropalliative care, provided clinical thoughts and perspectives on National Women Physicians Day and the ways to promote women leadership within the neurology field.